Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06263114 · ClinicalTrials.gov registry record
Correlation of Blood Gene Expression (TruGraf Liver) With Liver Biopsy in Pediatric Liver Transplant Recipients
A clinical trial, sponsored by Children's Mercy Hospital Kansas City.
- Terminated
- Registry status
- 16
- Enrollment target
NCT06263114: Clinical Trial study, sponsored by Children's Mercy Hospital Kansas City.
NCT06263114 is a clinical trial that was terminated before completion, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06263114 was terminated before completion, sponsored by Children's Mercy Hospital Kansas City.
- TERMINATED
- Registry status
- 16 participants
- Enrollment target
Study Summary
Liver transplant rejection is when the body's immune system attacks and damages the liver of a transplant recipient. Currently the best way to see if that is happening is with a liver biopsy. The purpose of this research study is to see if a simple blood test can diagnose if a transplanted liver is being rejected.
Primary Outcome
To evaluate the performance of the blood-based TruGraf® Liver GEP to accurately diagnose rejection, confirmed by surveillance or for-cause liver biopsy.
Interventions
- DIAGNOSTIC_TEST TruGraf® Liver gene expression panel (GEP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2024-01-01 |
| Est. Completion | 2025-02-07 |
Why NCT06263114 stopped before completion
NCT06263114 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which TruGraf® Liver gene expression panel (GEP) is the first listed.
NCT06263114 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06263114 about?
NCT06263114 is a clinical study titled "Correlation of Blood Gene Expression (TruGraf Liver) With Liver Biopsy in Pediatric Liver Transplant Recipients". Liver transplant rejection is when the body's immune system attacks and damages the liver of a transplant recipient. Currently the best way to see if that is happening is with a liver biopsy. The purpose of this research study is to see if a simple blood test can diagnose if a transplanted liver is ...
What is the current status of trial NCT06263114?
This trial is currently terminated. The enrollment target is 16 participants. The study started on 2024-01-01. Estimated completion is 2025-02-07.
What interventions are being tested in trial NCT06263114?
The interventions under investigation include: TruGraf® Liver gene expression panel (GEP) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06263114?
This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI